An international registry of patients with plasminogen deficiency (HISTORY)

Amy D Shapiro, Marzia Menegatti, Roberta Palla, Marco Boscarino, Christopher Roberson, Paolo Lanzi, Joel Bowen, Charles Nakar, Isaac A Janson, Flora Peyvandi, Amy D Shapiro, Marzia Menegatti, Roberta Palla, Marco Boscarino, Christopher Roberson, Paolo Lanzi, Joel Bowen, Charles Nakar, Isaac A Janson, Flora Peyvandi

Abstract

Plasminogen deficiency is an ultra-rare multisystem disorder characterized by the development of fibrin-rich pseudomembranes on mucous membranes. Ligneous conjunctivitis, which can result in vision impairment or loss, is the most frequent symptom reported. Affected systems may also include the respiratory tract, oropharynx, female reproductive tract, gingiva, middle ear, renal collecting system, skin and central nervous system. Untreated, plasminogen deficiency may result in significant reduction in quality of life and morbidity with potential life-threatening complications. Non-specific therapies are inadequate and plasminogen concentrates are not commercially available. The current understanding of plasminogen deficiency and management of disease symptoms and its progression are based on case reports/series and two small clinical trials. To date there has never been a comprehensive, international study to examine the natural history or optimal therapeutic intervention; knowledge gaps include identification of contributing factors and triggers of disease manifestations, inability to predict disease course, and insufficient real-world data for use of therapeutics. We have created an international, observational study (HISTORY) in a large cohort of persons with plasminogen deficiency and first-degree family members to address these gaps and to advance knowledge and care. HISTORY will build upon the established relationship between the Indiana Hemophilia and Thrombosis Center and the Fondazione Angelo Bianchi Bonomi, IRCCS Ca' Granda Ospedale Maggiore Policlinico - University of Milan and will utilize a modified version of the Prospective Rare Bleeding Disorders Database (PRO-RBDD). A biorepository containing samples from subjects with plasminogen deficiency will be established. This article describes the rationale behind the study and efforts towards its goals.

Copyright© 2020 Ferrata Storti Foundation.

Figures

Figure 1
Figure 1
Overall study timeline and scheduled study visits. (A) The 4-year study plan includes a 1-year enrollment period and a maximum 3-year on-study period for each subject enrolled. Retrospective clinical data for 1 year prior to study enrollment will also be collected. (B) The initial baseline visit will include informed consent, demographics, screening, laboratory investigations, genetic testing, medical examination and history, and a 1-year retrospective collection of relevant clinical data. Subsequent study visits will occur every 6 months and will include a medical history review; the closeout visit will occur at the 3-year time point. See also Table 3.

References

    1. Forrest CB, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet.2011;377(9771):1057–1059.
    1. Jansen-van der Weide MC, Gaasterland CMW, Roes KCB, et al. Rare disease registries: potential applications towards impact on development of new drug treatments. Orphanet J Rare Dis.2018;13(1):154.
    1. Schuster V, Hugle B, Tefs K. Plasminogen deficiency. J Thromb Haemost.2007;5(12): 2315–2322.
    1. Tait RC, Walker ID, Conkie JA, et al. Plasminogen levels in healthy volunteers–influence of age, sex, smoking and oral contraceptives. Thromb Haemost.1992;68(5): 506–510.
    1. Tait RC, Walker ID, Conkie JA, Islam SI, McCall F. Isolated familial plasminogen deficiency may not be a risk factor for thrombosis. Thromb Haemost.2018;76(6):1004–1008.
    1. Tefs K, Tait CR, Walker ID, Pietzsch N, Ziegler M, Schuster V. A K19E missense mutation in the plasminogen gene is a common cause of familial hypoplasminogenaemia. Blood Coagul Fibrinolysis.2003;14(4):411–416.
    1. Dykes D, Polesky H. Incidence of the PLG* QO allele in human populations. In: Mayr WR, ed. Advances in Forensic Haemogenetics: Springer-Verlag; Berlin Heidelberg, 1988:261–264.
    1. Okamoto A, Sakata T, Mannami T, et al. Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita study. J Thromb Haemost.2003;1 (11):2397–2403.
    1. Weidinger S, Patutschnick W, Schwarzfischer F. Further evidence of a silent plasminogen (PLG) allele in two paternity cases. Z Rechtsmed.1988;101(2):99–104.
    1. Mehta R, Shapiro AD. Plasminogen deficiency. Haemophilia.2008;14(6):1261–1268.
    1. Schuster V, Seregard S. Ligneous conjunctivitis. Surv Ophthalmol.2003;48(4):369–388.
    1. Klammt J, Kobelt L, Aktas D, et al. Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity. Thromb Haemost.2011;105(3):454–460.
    1. Tefs K, Gueorguieva M, Klammt J, et al. Molecular and clinical spectrum of type I plasminogen deficiency: a series of 50 patients. Blood.2006;108(9):3021–3026.
    1. Shapiro AD, Nakar C, Parker JM, et al. Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood.2018;131(12):1301–1310.
    1. Pantanowitz L, Bauer K, Tefs K, et al. Ligneous (pseudomembranous) inflammation involving the female genital tract associated with type-1 plasminogen deficiency. Int J Gynecol Pathol.2004;23 (3):292–295.
    1. Chi AC, Prichard E, Richardson MS, Rasenberger KP, Weathers DR, Neville BW. Pseudomembranous disease (ligneous inflammation) of the female genital tract, peritoneum, gingiva, and paranasal sinuses associated with plasminogen deficiency. Ann Diagn Pathol.2009;13(2):132–139.
    1. Cohen J, Cohen S, Cymberknoh MC, Gross M, Hirshoren N, Shoseyov D. Laryngeal obstruction in congenital plasminogen deficiency. Pediatr Pulmonol.2012;47(9):923–925.
    1. Ciftci E, Ince E, Akar N, Dogru U, Tefs K, Schuster V. Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency. Eur J Pediatr.2003;162(7-8):462–465.
    1. Weinzierl MR, Collmann H, Korinth MC, Gilsbach JM, Rohde V. Management of hydrocephalus in children with plasminogen deficiency. Eur J Pediatr Surg.2007;17(2):124–128.
    1. Schott D, Dempfle CE, Beck P, et al. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N Engl J Med.1998;339(23):1679–1686.
    1. Martin-Fernandez L, Marco P, Corrales I, et al. The unravelling of the genetic architecture of plasminogen deficiency and its relation to thrombotic disease. Sci Rep.2016;6:39255.
    1. Hidayat AA, Riddle PJ. Ligneous conjunctivitis. A clinicopathologic study of 17 cases. Ophthalmology.1987;94(8):949–959.
    1. De Cock R, Ficker LA, Dart JG, Garner A, Wright P. Topical heparin in the treatment of ligneous conjunctivitis. Ophthalmology.1995;102(11):1654–1659.
    1. Holland EJ, Chan CC, Kuwabara T, Palestine AG, Rowsey JJ, Nussenblatt RB. Immunohistologic findings and results of treatment with cyclosporine in ligneous conjunctivitis. Am J Ophthalmol.1989;107(2):160–166.
    1. Shimabukuro M, Iwasaki N, Nagae Y, et al. Ligneous conjunctivitis: a case report. Jap J Ophthalmol.2001;45(4):375–377.
    1. Firat T. Ligneous conjunctivitis. Am J Ophthalmol.1974;78(4):679–688.
    1. Sartori MT, Saggiorato G, Pellati D, et al. Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. Thromb Haemost.2003;89(01):86–91.
    1. Fine G, Bauer K, Al-Mohaya M, Woo SB. Successful treatment of ligneous gingivitis with warfarin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.2009;107(1):77–80.
    1. Barabino S, Rolando M. Amniotic membrane transplantation in a case of ligneous conjunctivitis. Am J Ophthalmol.2004;137 (4):752–753.
    1. Tabbara KF. Prevention of ligneous conjunctivitis by topical and subconjunctival fresh frozen plasma. Am J Ophthalmol.2004;138 (2):299–300.
    1. Kizilocak H, Ozdemir N, Dikme G, et al. Treatment of plasminogen deficiency patients with fresh frozen plasma. Pediatr Blood Cancer.2018;65(2):e26779.
    1. Watts P, Suresh P, Mezer E, et al. Effective treatment of ligneous conjunctivitis with topical plasminogen. Am J Ophthalmol.2002;133(4):451–455.
    1. Pons V, Olivera P, Garcia-Consuegra R, et al. Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. J Thromb Thrombolysis.2016;41 (3):544–547.
    1. Nakar CT, Caputo R, Price FW, et al. Safety & efficacy of human plasma derived plasminogen ophthalmic drops for treatment of ligneous conjunctivitis: report of phase 2/3 clinical trial. Blood.2015;126(23):2288.
    1. O’Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia.2013;19(4):e239–247.
    1. Keipert C, Hesse J, Haschberger B, et al. The growing number of hemophilia registries: quantity vs. quality. Clin Pharmacol Ther.2015;97(5):492–501.
    1. Osooli M, Berntorp E. Inhibitors in haemophilia: what have we learned from registries? A systematic review. J Intern Med.2015;277(1):1–15.
    1. European Medicines Agency Report on Haemophilia Registries; Workshop 8 June 2018; Patient Registries Initiative [cited September 23, 2019]; Available from:
    1. Gupta S, Acharya S, Roberson C, Lail A, Soucie JM, Shapiro A. Potential of the Community Counts registry to characterize rare bleeding disorders. Haemophilia.2019;25(6):1045–1050.
    1. Konkle BA, Johnsen JM, Wheeler M, et al. Genotypes, phenotypes and whole genome sequence: approaches from the My Life Our Future haemophilia project. Haemophilia.2018;24Suppl 6:87–94.
    1. Centers for Disease Control and Prevention Community Counts. [cited September 24, 2019]; Available from:
    1. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost.2012;10(4):615–621.
    1. Peyvandi F, Di Michele D, Bolton-Maggs PH, et al. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost.2012;10(9):1938–1943.
    1. European Association for Haemophilia and Allied Disorders Prospective Rare Bleeding Disorders Database (PRO-RBDD). [cited September 23, 2019]; Available from:
    1. Menegatti M, Palla R, Boscarino M, et al. Minimal factor XIII activity level to prevent major spontaneous bleeds. J Thromb Haemost.2017;15(9):1728–1736.
    1. Iorio A, Keepanasseril A, Foster G, et al. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): study protocol. JMIR Res Protoc.2016;5(4):e239.
    1. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb.2003;33 (1):4–15.
    1. Chitlur M, Sorensen B, Rivard GE, et al. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia.2011;17(3):532–537.
    1. van Geffen M, Loof A, Lap P, et al. A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis. Hematology.2011;16(6):327–336.
    1. Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood.2004;103(6):2157–2161.
    1. Ma Q, Ozel AB, Ramdas S, et al. Genetic variants in PLG, LPA, and SIGLEC 14 as well as smoking contribute to plasma plasminogen levels. Blood.2014;124(20):3155–3164.
    1. Li JF, Lin Y, Yang YH, et al. Fibrinogen Aalpha Thr312Ala polymorphism specifically contributes to chronic thromboembolic pulmonary hypertension by increasing fibrin resistance. PLoS One.2013;8 (7):e69635.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅